Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012
Dinmohamed, A G, Visser, O, van Norden, Y, Blijlevens, N M A, Cornelissen, J J, Huls, G A, Huijgens, P C, Sonneveld, P, van de Loosdrecht, A A, Ossenkoppele, G J, Löwenberg, B, Jongen-Lavrencic, M
Published in Leukemia (01.01.2016)
Published in Leukemia (01.01.2016)
Get full text
Journal Article
miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression
Wang, M, Tan, LP, Dijkstra, MK, van Lom, K, Robertus, J.L, Harms, G, Blokzijl, T, Kooistra, K, van t'Veer, MB, Rosati, S, Visser, L, Jongen-Lavrencic, M, Kluin, PM, van den Berg, A
Published in The Journal of pathology (01.05.2008)
Published in The Journal of pathology (01.05.2008)
Get full text
Journal Article
P406: ENHANCED SIGNIFICANCE OF FLT3‐ITD RESIDUAL DISEASE DETECTION ON TREATMENT OUTCOME IN ACUTE MYELOID LEUKEMIA
Grob, T., Sanders, M., Vonk, C., Kavelaars, F., Rijken, M., Hanekamp, D., Gradowska, P., Cloos, J., Fløisand, Y., Marwijk Kooy, M. V., Manz, M., Ossenkoppele, G., Tick, L., Havelange, V., Löwenberg, B., Jongen‐Lavrencic, M., Valk, P.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years
Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Beverloo, H B, Valk, P J M, van Marwijk Kooy, M, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, M-C, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, C, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G, Löwenberg, B
Published in Leukemia (01.05.2015)
Published in Leukemia (01.05.2015)
Get full text
Journal Article
Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival
Dinmohamed, A G, Szabó, A, van der Mark, M, Visser, O, Sonneveld, P, Cornelissen, J J, Jongen-Lavrencic, M, Rijneveld, A W
Published in Leukemia (01.02.2016)
Published in Leukemia (01.02.2016)
Get full text
Journal Article
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
van de Loosdrecht, A A, Cremers, E M P, Alhan, C, Duetz, C, In 't Hout, F E M, Visser-Wisselaar, H A, Chitu, D A, Verbrugge, A, Cunha, S M, Ossenkoppele, G J, Janssen, J J W M, Klein, S K, Vellenga, E, Huls, G A, Muus, P, Langemeijer, S M C, de Greef, G E, Te Boekhorst, P A W, Raaijmakers, M H G, van Marwijk Kooy, M, Legdeur, M C, Wegman, J J, Deenik, W, de Weerdt, O, van Maanen-Lamme, T M, Jobse, P, van Kampen, R J W, Beeker, A, Wijermans, P W, Biemond, B J, Tanis, B C, van Esser, J W J, Schaar, C G, Noordzij-Nooteboom, H S, Jacobs, E M G, de Graaf, A O, Jongen-Lavrencic, M, Stevens-Kroef, M J P L, Westers, T M, Jansen, J H
Published in Leukemia (01.04.2024)
Published in Leukemia (01.04.2024)
Get full text
Journal Article
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
Janssen, J. J. W. M., Löwenberg, B., Manz, M., Biemond, B. J., Westerweel, P. E., Klein, S. K., Fehr, M., Sinnige, H. A. M., Efthymiou, A., Legdeur, M. C. J. C., Pabst, T., Gregor, M., van der Poel, M. W. M., Deeren, D., Tick, L. W., Jongen-Lavrencic, M., van Obbergh, F., Boersma, R. S., de Weerdt, O., Chalandon, Y., Heim, D., Spertini, O., van Sluis, G., Graux, C., Stüssi, G., van Norden, Y., Ossenkoppele, G. J.
Published in Leukemia (01.09.2022)
Published in Leukemia (01.09.2022)
Get full text
Journal Article
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, van der Klift, M, van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, M W M, van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B
Published in Leukemia (01.07.2020)
Published in Leukemia (01.07.2020)
Get full text
Journal Article
Web Resource
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
Dinmohamed, A G, van Norden, Y, Visser, O, Posthuma, E F M, Huijgens, P C, Sonneveld, P, van de Loosdrecht, A A, Jongen-Lavrencic, M
Published in Leukemia (01.12.2015)
Published in Leukemia (01.12.2015)
Get full text
Journal Article
The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML
Sun, S M, Rockova, V, Bullinger, L, Dijkstra, M K, Döhner, H, Löwenberg, B, Jongen-Lavrencic, M
Published in Leukemia (01.01.2013)
Published in Leukemia (01.01.2013)
Get full text
Journal Article
Aberrant expression of miR-9/9 in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG
Nowek, K, Sun, S M, Bullinger, L, Bindels, E M J, Exalto, C, Dijkstra, M K, van Lom, K, Döhner, H, Erkeland, S J, Löwenberg, B, Jongen-Lavrencic, M
Published in Leukemia (01.01.2016)
Published in Leukemia (01.01.2016)
Get full text
Journal Article
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Ossenkoppele, G. J, Breems, D. A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B. J, A von dem Borne, P
Published in Leukemia (01.10.2020)
Published in Leukemia (01.10.2020)
Get full text
Journal Article
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Hilberink, Jacobien R, van Zeventer, Isabelle A, Chitu, Dana A, Pabst, Thomas, Klein, Saskia K, Stussi, Georg, Griskevicius, Laimonas, Valk, Peter J M, Cloos, Jacqueline, van de Loosdrecht, Arjan A, Breems, Dimitri, van Lammeren-Venema, Danielle, Boersma, Rinske, Jongen-Lavrencic, Mojca, Fehr, Martin, Hoogendoorn, Mels, Manz, Markus G, Söhne, Maaike, van Marwijk Kooy, Rien, Deeren, Dries, van der Poel, Marjolein W M, Legdeur, Marie Cecile, Tick, Lidwine, Chalandon, Yves, Ammatuna, Emanuele, Blum, Sabine, Löwenberg, Bob, Ossenkoppele, Gert J, Huls, Gerwin
Published in Blood cancer journal (New York) (19.06.2023)
Published in Blood cancer journal (New York) (19.06.2023)
Get full text
Journal Article
MicroRNA signatures characterize multiple myeloma patients
CORTHALS, S. L, SUN, S. M, ZWEEGMAN, S, JONGEN-LAVRENCIC, M, SONNEVELD, P, KUIPER, R, DE KNEGT, Y, BROYL, A, VAN DER HOLT, B, BEVERLOO, H. B, PEETERS, J. K, EL JARARI, L, LOKHORST, H. M
Published in Leukemia (01.11.2011)
Published in Leukemia (01.11.2011)
Get full text
Journal Article
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
Dinmohamed, A G, van Norden, Y, van de Loosdrecht, A A, Jongen-Lavrencic, M
Published in Leukemia (01.08.2016)
Published in Leukemia (01.08.2016)
Get full text
Journal Article
17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation
DIJKSTRA, M. K, VAN LOM, K, TIELEMANS, D, ELSTRODT, F, LANGERAK, A. W, VAN 'T VEER, M. B, JONGEN-LAVRENCIC, M
Published in Leukemia (01.03.2009)
Published in Leukemia (01.03.2009)
Get full text
Journal Article